Abstract
It has been estimated that two-thirds of the world population have thyroid nodules,1 and their incidence increases with age.2 While most are benign,1 the incidence of thyroid cancer has increased substantially worldwide over the last four decades.3 Therefore, there is a need for reliable methods of thyroid nodule evaluation. Fine-needle biopsy with cytologic evaluation remains the standard diagnostic test to distinguish benign from malignant thyroid nodules but has a number of limitations, including its inability to identify aggressive tumors.4 In an expert interview, Dr Hossein Gharib of the Mayo Clinic College of Medicine, Rochester, MN, discusses the need for molecular testing in thyroid cancer.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
